Herantis Pharma PLC · OMXHEX:HRTIS
Herantis Pharma — TreatER Webcast (November 2020)
13 slides from Herantis Pharma's conference presentation, Nov 18, 2020
Slide 1: CDNF in the First-in-Human Clinical Trial
CDNF in the First-in-Human Clinical Trial 12 months clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s Magnus Sjögren, Chief Medical Officer at Herantis Pharma Plc. And Professor Per Svenningsson, Principal Investigator, Karoli
Slide 2: The Clinical Trial
The Clinical Trial The primary endpoint of this First-in-Human study was safety and tolerability Ø secondary endpoints included evaluation of efficacy of CDNF 17 patients with Parkinson’s disease The clinical trial was conducted at 3 clinical sites and 2 PET centers in Finland and Sweden – Karolinsk
Slide 3: The Clinical Trial Design and Characteristics
The Clinical Trial Design and Characteristics Main Study – 6 months Extension Study – 6 months Follow-up Study – 4 years Treatment groups Mid-dose CDNF Vehicle (n=6) High-dose CDNF Safety follow-up Mid-dose CDNF (n=6) All patients High-dose CDNF (n=5) Safety Follow-up, Monthly Infusions x 6 Monthly
Slide 4: Clinical Trial Procedures
Clinical Trial Procedures Altogether 26 Visits Over A Period Of 16 Months v 12 treatment infusions, once every month Many Scans Taken For Surgical Planning And Safety Neurosurgical Implantation Of The Drug Delivery Device Several Off-medication Session With Stay Overnight, Travel to PET-Centre, Diar
Slide 5: Renishaw's Drug Delivery System
Renishaw’s Drug Delivery System © 2014-2020 HERANTIS PHARMA Plc. All rights reserved. 5
Slide 6: CDNF in the First-in-Human clinical trial 12 Months Primary Endpoint - Safety
CDNF in the First-in-Human clinical trial 12 Months Primary Endpoint - Safety
Slide 7: Safety Assessment During the Clinical Trial
Safety Assessment During the Clinical Trial Safety Was Assessed At Any Time During The Study: • By asking the patient if they have experienced any new adverse events since the previous visit, also events unrelated to the study treatment Laboratory Blood And Urine Testing At Every Visit • Also testin
Slide 8: Observed Adverse Events Profile
Observed Adverse Events* Profile NERVOUS SYSTEM DISORDERS GENERAL DISORDERS AND ADMINISTRATION SITE 9% CONDITIONS PSYCHIATRIC DISORDERS 10 % 29 % INJURY, POISONING AND PROCEDURAL COMPLICATIONS 5% INFECTIONS AND INFESTATIONS GASTROINTESTINAL DISORDERS 6% MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDER
Slide 9: The Most Common Reported Drug-Related Adverse Events
The Most Common Reported Drug-Related Adverse Events Altogether 68 Drug-related Adverse Events Were Reported During the 12-Month Treatment Period Were Mild to Moderate, and Majority Has Recovered: Central Nervous General Other Disorders System Disorders Disorders Dyskinesias, Headache, Feeling cold,
Slide 10: Serious Adverse (Device) Events
Serious Adverse (Device) Events Altogether 9 serious adverse (device) events were reported in the Main and Extension study: • 1 serious event occured prior to surgery or treatment start – purulent sinusitis • 5 serious adverse events occuring after surgery, prior to treatment start: ○ Confusion (2x)
Slide 11: All Recovered from Serious Adverse (Device) Events
All Recovered from Serious Adverse (Device) Events • Brain abscess occured in Main study during the first 6-month period Infectious events: • Port skin necrosis in Main study during the first 6-month period Risk mitigation improvements made to surgical procedure, infusion procedure, device maintenan
Slide 12: Summary of 12-Month Safety Data
Summary of 12-Month Safety Data 12 Monthly Intracerebral Doses of CDNF was Safe and Well-Tolerated Majority of the Reported Drug-related Adverse Events Were Mild And all Patients have Recovered Similar Safety Profile in Main and Extension Study, Less Reported Adverse Events in Extension ○ No clear d
Slide 13: Thank you!
Thank you! 24 11/20/20 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.